MAXIM RECEIVES U.S. PATENT FOR APOPTOSIS INDUCERS

Maxim Pharmaceuticals has been issued a U.S. patent 6,906,203, titled "Substituted 4H-Chromene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof."

The patent covers a novel class of potent apoptosis inducers with vascular targeting activity that inhibit microtubule formation. The lead compound in this series is MX2407, which has strong antitumor activity in preclinical in vitro and in vivo studies and is being advanced for clinical development.